ReviewRadiology2023
MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma: A Consensus Statement.
Review in Radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- ESR Essentials: uterine cancers-practice recommendations by the European Society of Urogenital Radiology.European radiology · 2026Guideline
- MRI for diagnosing uterine sarcoma: a systematic review and meta-analysis.Japanese journal of radiology · 2026Pooled it
- Magnetic resonance imaging features of uterine adenosarcoma: case series and systematic review.Abdominal radiology (New York) · 2025Pooled it
- Comparing different techniques of uterine artery occlusion during laparoscopic myomectomy: a randomized controlled trial.BMC women's health · 2026Trial
- Uterine mesenchymal tumors: development and preliminary results of a magnetic resonance imaging (MRI) diagnostic algorithm.La Radiologia medica · 2023Trial
- Development and External Testing of an Interpretable MRI-Based Machine Learning Model for Differentiating Endometrial Stromal Sarcoma from Cellular Leiomyoma.Journal of imaging informatics in medicine · 2026Article
- Advances in uterine sarcoma management: A mini-review of clinical practice and molecular insights.Gynecologic oncology reports · 2026Review
- Gynecologic imaging errors and pitfalls: how to avoid misdiagnosis on pelvic MRI.Insights into imaging · 2026Review
- Multicenter Study of MRI Features in Uterine Myxoid Leiomyosarcoma: Revealing and Overcoming a Critical Pitfall in Current Consensus Criteria.Korean journal of radiology · 2026Article
- Metastatic Uterine Sarcomas: A Retrospective Analysis on Clinical Outcomes and Biology.Cureus · 2026Article
- Secondary peritoneal leiomyomatosis after uterine leiomyoma intervention: multi-institutional clinical and radiologic experience.Abdominal radiology (New York) · 2026Article
- Cervical embryonal rhabdomyosarcoma beyond childhood: A case report and literature review.Radiology case reports · 2026Article
- Biparametric MRI-based nomogram for differentiating malignant from atypical benign uterine smooth muscle tumors.Abdominal radiology (New York) · 2026Article
- Mapping Metastatic Spread in Uterine Sarcoma: A Population-Based Analysis of First Metastatic Patterns and Outcomes.Cancers · 2026Article
- Rare and uncommon tumours of the female pelvis: what the radiologist should know.The British journal of radiology · 2026Review
- Comparison of MR Imaging of High-grade Serous Carcinomas with and without Homologous Recombination-deficiency.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- Development of a blood test for uterine sarcoma-Diagnosis and monitoring (DOORS-D and DOORS-M) studies.PloS one · 2026Article
- Uterine sarcoma: A 10-year retrospective analysis of clinicopathological and prognostic factors of surgically treated cases.Ecancermedicalscience · 2026Article
- Plasma Proteome-Wide Mendelian Randomization with Multi-Layer Triangulation Identifies Druggable Targets for Uterine Leiomyoma.International journal of women's health · 2026Article
- Fertility preservation in the setting of a new uterine smooth muscle tumor of uncertain malignant potential (STUMP) diagnosis.Gynecologic oncology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 3 countries.
Funding
Abstract
Laparoscopic myomectomy, a common gynecologic operation in premenopausal women, has become heavily regulated since 2014 following the dissemination of unsuspected uterine leiomyosarcoma (LMS) throughout the pelvis of a physician treated for symptomatic leiomyoma. Research since that time suggests a higher prevalence than previously suspected of uterine LMS in resected masses presumed to represent leiomyoma, as high as one in 770 women (0.13%). Though rare, the dissemination of an aggressive malignant neoplasm due to noncontained electromechanical morcellation in laparoscopic myomectomy is a devastating outcome. Gynecologic surgeons' desire for an evidence-based, noninvasive evaluation for LMS is driven by a clear need to avoid such harms while maintaining the availability of minimally invasive surgery for symptomatic leiomyoma. Laparoscopic gynecologists could rely upon the distinction of higher-risk uterine masses preoperatively to plan oncologic surgery (ie, potential hysterectomy) for patients with elevated risk for LMS and, conversely, to safely offer women with no or minimal indicators of elevated risk the fertility-preserving laparoscopic myomectomy. MRI evaluation for LMS may potentially serve this purpose in symptomatic women with leiomyomas. This evidence review and consensus statement defines imaging and disease-related terms to allow more uniform and reliable interpretation and identifies the highest priorities for future research on LMS evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.